Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.56 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8454150 | 0.84 | HTR7 (0.56) | HTR7RORCSCN9AALDH1A1LMNA | |
| SCHEMBL13931127 | 0.83 | HTR7 (0.43) | HTR7MCL1RORCSCN9AALDH1A1 | |
| SCHEMBL6952151 | 0.80 | PLA2G4A (0.56) | HTR7RORCSCN9ACDC25A | |
| SCHEMBL13931128 | 0.79 | CDC25A (0.42) | HTR7MCL1RORCALDH1A1LMNA | |
| SCHEMBL28379252 | 0.78 | SCN9A (0.65) | HTR7SCN9ATNF | |
| SCHEMBL8173558 | 0.77 | ALDH1A1 (0.50) | HTR7MCL1RORCSCN9AALDH1A1 | |
| SCHEMBL8173717 | 0.77 | PLK1 (0.42) | HTR7MCL1RORCSCN9AALDH1A1 | |
| SCHEMBL8175039 | 0.77 | ALDH1A1 (0.42) | HTR7MCL1RORCSCN9AALDH1A1 | |
| SCHEMBL27519888 | 0.77 | SCN9A (0.51) | HTR7RORCSCN9AALDH1A1TNF | |
| SCHEMBL8174649 | 0.75 | ALDH1A1 (0.57) | HTR7MCL1RORCALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008100867-A2 | NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | HTR7 4326/4885MCL1 2836/4885RORC 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.